Brainstorm Cell Therapeutics Management

Management criteria checks 1/4

Brainstorm Cell Therapeutics' CEO is Chaim Lebovits, appointed in Jan 2023, has a tenure of 1.33 years. total yearly compensation is $1.13M, comprised of 39.1% salary and 60.9% bonuses, including company stock and options. directly owns 1.26% of the company’s shares, worth €347.75K. The average tenure of the management team and the board of directors is 1.8 years and 6.2 years respectively.

Key information

Chaim Lebovits

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage	39.1%
CEO tenure	1.3yrs
CEO ownership	1.3%
Management average tenure	1.8yrs
Board average tenure	6.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chaim Lebovits's remuneration changed compared to Brainstorm Cell Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$442k	-US$17m
Sep 30 2023	n/a	n/a	-US$17m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$1m	US$500k	-US$24m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$24m
Mar 31 2022	n/a	n/a	-US$23m
Dec 31 2021	US$1m	US$500k	-US$24m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$2m	US$500k	-US$32m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$29m
Mar 31 2020	n/a	n/a	-US$26m
Dec 31 2019	US$1m	US$500k	-US$23m
Sep 30 2019	n/a	n/a	-US$21m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$17m
Dec 31 2018	US$2m	US$500k	-US$14m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$1m	US$391k	-US$5m

Compensation vs Market: Chaim's total compensation ($USD1.13M) is above average for companies of similar size in the German market ($USD396.12K).

Compensation vs Earnings: Chaim's compensation has increased whilst the company is unprofitable.

CEO

Chaim Lebovits (52 yo)

1.3yrs

Tenure

US$1,128,795

Compensation

Mr. Chaim Lebovits is President & Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from January 2023. Mr. Lebovits was Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from April...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Chaim Lebovits	President & Co-CEO	1.3yrs	US$1.13m	1.26% $ 347.8k
Stacy Lindborg	Co-Chief Executive Officer	1.3yrs	US$1.01m	0.62% $ 171.5k
Irit Arbel	Co-Founder & Independent Vice Chair of the Board	20yrs	no data	0.23% $ 63.1k
Alla Patlis	Interim CFO & Controller	11.4yrs	US$146.78k	0.095% $ 26.4k
Uri Yablonka	Executive VP	7.2yrs	US$247.06k	0.19% $ 51.4k
Daniel Offen	Chief Scientific Advisor	no data	no data	no data
Mary Turner	Senior Vice President of Patient Advocacy & Government Affairs	2.3yrs	no data	no data
Ibrahim Dagher	Executive VP & Chief Medical Officer	less than a year	no data	0.37% $ 102.5k

1.8yrs

Average Tenure

52yo

Average Age

Experienced Management: GHDN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Irit Arbel	Co-Founder & Independent Vice Chair of the Board	20yrs	no data	0.23% $ 63.1k
Uri Yablonka	Executive VP	9.9yrs	US$247.06k	0.19% $ 51.4k
Jacob Frenkel	Independent Chairman of the Board	4.2yrs	US$152.81k	0.083% $ 23.0k
Stanley Appel	Member of Scientific Advisory Board	no data	no data	no data
Andrew Card	Member of Business Advisory Board	13.2yrs	no data	no data
Amit Bar-Or	Member of Scientific Advisory Board	no data	no data	no data
Menghisteab Bairu	Independent Director	2.6yrs	no data	no data
Rasheda Ali	Member of Business Advisory Board	16.6yrs	no data	no data
Jerold Chun	Chairman of Scientific Advisory Board	6.2yrs	no data	no data
Anthony Polverino	Independent Director	6.3yrs	US$24.61k	0.038% $ 10.5k
Ralph Kern	Member of Scientific Advisory Board	1.3yrs	US$812.56k	0% $ 0
Nir Naor	Independent Director	less than a year	no data	0% $ 0

6.2yrs

Average Tenure

63yo

Average Age

Experienced Board: GHDN's board of directors are considered experienced (6.2 years average tenure).

Brainstorm Cell Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Brainstorm Cell Therapeutics Inc. Announces Management Changes

Brainstorm Cell Therapeutics Inc. Announces Executive Changes

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023

BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development Officer

Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating Officer

Recent updates

Brainstorm Cell Therapeutics Inc. Announces Management Changes

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS

New major risk - Shareholder dilution

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS

Brainstorm Cell Therapeutics Inc. Announces Executive Changes

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

Brainstorm Cell Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance Market Value of Listed Securities Requirement for Continued Listing on The Nasdaq Capital Market

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc

BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS

New minor risk - Profitability

Brainstorm Cell Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023

BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development Officer

Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

New minor risk - Market cap size

Forecast to breakeven in 2025

Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating Officer

Forecast to breakeven in 2025

No longer forecast to breakeven

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer

Brainstorm Cell Therapeutics Inc. Announces Type A Meeting with FDA Granted for NurOwn®

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Jan 10, 2023

BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration

Brainstorm Cell Therapeutics Seeks FDA Approval of Mesenchymal Stem Cell Therapy Called NurOwn for the Treatment of ALS

Brainstorm Cell Therapeutics Inc. Receives Refusal to File Letter from FA for Its New Biologics License Application for Nurown for the Treatment of Als

BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium

Brainstorm Cell Therapeutics Inc. Announces Peer Reviewed Publication of Results from the Nurown Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

Brainstorm Cell Therapeutics Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for NurOwn for the Treatment of Amyotrophic Lateral Sclerosis

Brainstorm Cell Therapeutics Inc. Appoints Antal Pearl-Lendner as Chief Legal Counsel

BrainStorm Cell Therapeutics Inc. Announces Presentation of Nurown® Exosome Preclinical Data At ISCT 2022 San Francisco Meeting

U.S. Food and Drug Administration Authorizes Further Brainstorm Cell Therapeutics Inc.'s Nurown Dosing Under Expanded Access Program

Brainstorm Cell Therapeutics Announces Peer Reviewed Publication of Nurown's® Phase 3 Study for Als in Muscle and Nerve

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium

No longer forecast to breakeven

Brainstorm Cell Therapeutics Inc.(NasdaqCM:BCLI) dropped from Russell 3000 Growth Index

New 90-day low: €3.28

Brainstorm Cell Therapeutics Inc. Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program

Brainstorm Cell Therapeutics Inc. Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan

Brainstorm Cell Therapeutics Inc. to Report Q4, 2020 Results on Feb 04, 2021

BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS

Brainstorm Cell Therapeutics Inc. Announces Completion of All Dosing in NurOwn® Phase 2 MS Study

BrainStorm Announces NurOwn® Expanded Access Program

New 90-day low: €3.42

BrainStorm Cell Therapeutics Inc. Announces Topline Results from NurOwn® Phase 3 ALS Study

New 90-day high: €14.80

Brainstorm Cell Therapeutics Inc. Appoints William K. White as Senior Vice President, Head of Market Access & Pricing

Brainstorm Cell Therapeutics Inc. to Report Q2, 2020 Results on Aug 03, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age